Top 50 Protein Engineering

The startup operates a biomedical tech platform that utilizes protein engineering, condensate biology, medicinal chemistry, and high-throughput microscopy screening to create biomolecular tools for therapeutic and synthetic biology applications. This platform enables researchers to develop targeted therapies for condensate-associated diseases and enhances the efficiency of synthetic biology research.

The startup develops immunity-boosting proteins using artificial intelligence, immunology, computational biology, and protein engineering to create safe proteins that do not trigger immune responses. This technology enables physicians to prescribe products that are safe for individuals with food allergies and gluten-related disorders.

The startup develops plant genetics technology to engineer plants that produce high-quality proteins, effectively replacing animal-derived food sources. This approach provides consumers with affordable and tasty alternatives to animal products while promoting a sustainable food system.

AminoAnalytica provides AMINA, an AI-native operating system that functions as a lab co-pilot for protein engineering workflows. This platform enables users to design novel proteins significantly faster by integrating computational tools like RFdiffusion and ProteinMPNN without requiring any coding or complex setup. AMINA offers on-demand access to enterprise-grade GPUs and a deep knowledge base to accelerate research, design, folding, and docking tasks.

Monod Bio develops computational protein design tools utilizing artificial intelligence to advance life sciences and clinical diagnostics. The company offers specialized products like NovoBody, LuxSit™ Pro, and NovoLISA for protein engineering applications. Their platform enables the creation of novel proteins with desired functionalities for various biological uses.

Tamarind Bio provides a unified platform for computational protein engineering, enabling the design and optimization of antibodies, enzymes, peptides, and small molecules. The service integrates state-of-the-art AI and physics-based tools like AlphaFold and RFdiffusion through an accessible interface. This allows scientists to rapidly predict structures, redesign sequences, and optimize developability properties at massive scale without complex setup.

Cradle offers an AI‑driven protein engineering platform that learns from a user’s experimental data and public datasets to generate and rank protein candidates across multiple objectives such as activity, binding affinity, stability, and expression. The cloud‑hosted workspace automates library design, runs large‑scale in‑silico simulations, and provides interactive visualizations to help scientists iterate rapidly, reducing the number of experimental rounds needed to meet target specifications.

BrickBio has developed a bioconjugation platform that enables site-specific modification of proteins, facilitating precise protein engineering for research applications. This technology enhances the study of protein functions and interactions, providing researchers with improved tools for understanding complex biological processes.

Lyterian Therapeutics develops disease‑modifying medicines by engineering proteins that engage the body’s natural homeostatic and healing pathways. Their platform combines mechanistic biology, protein engineering, and genetically validated targets to create candidates that restore physiological balance and aim for durable disease resolution, serving pharma and biotech partners seeking novel therapeutic approaches.

Treeline Biosciences develops precision medicines utilizing advanced protein engineering and computational biology to target specific cancer pathways and other serious diseases. The company aims to improve patient outcomes by creating tailored therapies that address the limitations of traditional treatment approaches.

Adaptyv Bio offers an automated cloud lab platform that conducts protein assays and delivers clean, labeled data for AI-driven protein design within three weeks. The service integrates ordering, experiment management, and data analysis through a comprehensive API, enabling seamless incorporation into existing workflows. Transparent per‑protein pricing and real‑time progress updates help teams accelerate lab‑in‑the‑loop protein engineering cycles.

Avenue Biosciences utilizes a machine learning-powered protein engineering platform to optimize protein production systems. This technology analyzes thousands of signal peptides to significantly enhance protein yield and quality for biotherapeutics and biotechnology tools. The platform is especially effective for improving the expression of difficult-to-produce mammalian proteins.

Profluent utilizes artificial intelligence to author novel proteins for diverse applications. Their platform designs custom protein sequences, including AI-designed gene editors like OpenCRISPR. This capability enables the creation of new solutions across therapeutics, agriculture, and industrial enzyme development.

Proteinea employs proprietary AI models and computational tools to engineer next-generation antibodies, enhancing their efficacy, safety, and convenience for therapeutic applications. The platform addresses the challenges of traditional protein engineering by optimizing protein characteristics and accelerating lead validation through a combination of advanced computational and experimental methods.

Pando uses AI-driven protein design and an ultra‑high‑throughput one‑pot screening platform to engineer enzymes with improved activity, stability, and manufacturability. It offers proprietary engineered enzymes for molecular biology workflows and custom enzyme development services that reduce costs and increase productivity for biotech companies and research labs.

Ohmic Biosciences combines protein engineering and synthetic biology to develop durable solutions for diseases affecting crops. Their technology enhances crop resilience, ensuring higher yields and reduced losses in agricultural production.

Paragon Therapeutics engineers novel biologic drug candidates using advanced protein engineering and high-throughput screening. Their integrated CMC model accelerates the progression of these therapies from discovery to clinical trials, addressing unmet medical needs.

ZipBio uses generative AI to design compact, multispecific protein therapeutics called Zip® drugs, enabling the creation of novel biologics that are difficult to produce with traditional methods. These smart proteins target unmet medical needs across various disease areas, and the company monetizes its pipeline through licensing, partnerships, and eventual product sales. The platform aims to accelerate drug development by compressing biological complexity into engineered therapeutic candidates.

Signify Bio develops personalized protein therapeutics by engineering signal peptides and leveraging mRNA‑encoded designs to control protein expression. Their platform enables rapid creation of nucleic‑acid‑enabled medicines tailored to individual patients, accelerating the development of targeted treatments.

Arzeda utilizes Intelligent Protein Design Technology™, combining physics-based protein design and AI, to create novel proteins and enzymes that enhance product performance across various industries. This approach addresses the need for sustainable and efficient alternatives in food production, personal care, and materials, reducing environmental impact while improving functionality.

Engimmune Therapeutics develops off-the-shelf soluble T-cell receptor (TCR) drugs using proprietary AI-guided protein engineering to enhance target affinity and stability for treating solid tumors. The company addresses the challenge of limited treatment options for solid tumors and immune-mediated diseases by rapidly identifying and engineering multi-specific TCRs for potent immune responses.

Sculpta builds Protein Sculpting™ therapeutics that modify the structure and function of disease‑causing proteins to treat neurodegeneration and brain aging. Their platform leverages the most comprehensive single‑cell data across the human brain and body to identify and engineer targets, aiming to reverse up to 90% of age‑related brain disorders. By integrating computational biology, machine learning, and large‑scale data pipelines, Sculpta accelerates discovery of novel neurotherapeutics.

This company develops a modular platform for the on-demand self-assembly of smart, multifunctional nanobiomaterials. Guided by a One Health approach, they are building business units focused on disease detection, prevention, and treatment. Their proprietary technology leverages expertise in protein engineering, immunology, and vaccinology to address global health challenges.

Juvena Therapeutics utilizes an AI-driven platform to identify and engineer secreted proteins into biologic therapeutics that restore tissue homeostasis. The company addresses the dysregulation of protein signaling that leads to degenerative diseases, including myopathies and metabolic disorders.

Adventris is a biotechnology company that creates cancer immunotherapies by engineering high‑affinity, tumor‑specific antibodies, immune checkpoint modulators, and adoptive cell therapies. Its platform integrates protein engineering, biomarker discovery, and GMP‑compliant manufacturing to develop candidates for partnership with pharma and biotech firms, aiming to deliver durable anti‑tumor treatments.

Bloom Labs utilizes bio-manufacturing and advanced protein engineering to convert natural waste by-products into high-performance pellets that can be spun into fibers, emulating the properties of cotton, silk, and polyester. This technology addresses the environmental impact of fossil fuel-based synthetic fibers, which contribute to microplastic pollution and are non-biodegradable.

Scala Biodesign utilizes a one-shot computational platform that combines evolutionary analysis and AI to enhance the stability, yield, and specificity of proteins for therapeutic and industrial applications. This technology addresses the limitations of natural proteins, which often lack the required resilience and efficiency for modern medical and manufacturing needs.

Aperiam Bio develops hyperfolding variants of proteins that significantly enhance expression, solubility, and specific activity, enabling the production of stable enzymes for various applications. Their technology addresses the instability of natural proteins in harsh conditions, ensuring over 68% activity retention in therapeutics and extending the shelf life of cosmetic ingredients.

AI Proteins designs de novo miniprotein medicines engineered from first principles for precise therapeutic function. This next-generation biologic modality offers high control over selectivity, stability, and pharmacokinetics, minimizing off-target effects and unwanted immune responses. The platform enables the rapid synthesis and validation of potent, programmable, and safe treatments tailored to specific patient needs.

Moab develops minibinder proteins—small, stable, and highly modular molecules—for therapeutic applications. By combining novel protein scaffolds, ultra‑high‑throughput data generation, and advanced AI models, they explore protein design space beyond the capabilities of current frontier AI methods, creating potent binders for partners. Their platform accelerates the discovery of new therapeutics by enabling the design of highly specific, high‑affinity minibinders at scale.

Onava offers an autonomous orchestration platform that links AI‑native protein engineering models with high‑throughput functional assays, creating a continuous learning loop across drug discovery programs. By aggregating variant data—from thousands to billions per campaign—into a cross‑program data flywheel, the system reuses experimental results to accelerate candidate optimization for biopharma and biotech firms.

The startup develops protein sequencing technology that enables pharmaceutical companies to generate antibody proteins directly from samples with high sequence accuracy and binding affinity. Their method utilizes mass spectrometry to restore hybridoma cell lines, confirm antibody products, and analyze post-translational modifications, facilitating the efficient development of biosimilars for improved human health.

Protogenix engineers novel proteins with tailored functionalities for therapeutic, industrial, and biomaterial applications. Our proprietary computational design and high-throughput screening platforms accelerate the development of custom proteins with enhanced efficacy, stability, and specificity.

This company engineers modular immunotherapies for cancer treatment by screening millions of protein candidates in living cells. They utilize a high-throughput screening platform coupled with machine learning to rapidly identify and design optimal therapeutic candidates. This integrated approach accelerates the development timeline, delivering best-in-class immunotherapies faster for clinical application.

Engivent provides an autonomous biology lab platform that turns experimental workflows into software-defined, high‑throughput processes. By integrating standard lab robotics with modular microfluidic systems, it can run hundreds of parallel conditions and close the loop between execution, readout, and iteration, enabling rapid protein engineering, therapeutic discovery, and synthetic biology. This infrastructure compresses design‑build‑test cycles from months to days, delivering fast, data‑rich feedback for AI‑generated molecular candidates.

The startup has developed a recombinant protein production technology that removes the origin of replication from bacterial chromosomes, allowing cells to remain metabolically active without dividing. This approach enables users to decouple protein production from cellular growth, enhancing yield and efficiency in biomanufacturing processes.

Change Bio provides an end‑to‑end platform that turns designed protein sequences into manufacturable strains and bioreactor‑scale protein samples. Their nsure service creates expressing *K. phaffii* strains within a week and enables high‑throughput library screening, while the rapid prototyping service delivers fed‑batch fermented protein samples that reflect industrial conditions, generating data to predict large‑scale manufacturability. Successful proteins can be licensed with the full strain‑construction, fermentation, and data infrastructure to scale production directly to commercial volumes.

Orbion provides an AI platform for comprehensive protein characterization, rational engineering, and automated experimental protocol generation. The platform integrates structure and omics data to predict PTMs, binding sites, and functional domains, accelerating discovery for diverse proteins and complexes. Researchers utilize Orbion to design optimized mutants and generate literature-validated bench protocols, significantly reducing wet-lab iteration time and cost.

MNDL Bio utilizes AI-driven computational models to optimize gene expression for recombinant protein production, significantly enhancing yield and reducing costs. The platform replaces traditional trial-and-error methods with precise, data-driven strain engineering, enabling faster time-to-market and improved sustainability in biotech and foodtech applications.

ALLOX utilizes systematic mutagenesis, high-throughput phenotyping, and biophysical modeling to identify allosteric switches in proteins, enabling the rapid development of novel therapeutics for human diseases. By harnessing genetics and AI, the company addresses the challenge of predicting and engineering protein functions, aiming to transform drug discovery and biotechnology.

RevivBio utilizes Generative AI and Ultrahigh Throughput experimentation to design proteins with enhanced functionality and efficiency. This approach addresses the challenges of traditional protein design by significantly increasing the success rate and speed of developing tailored proteins for various applications.

Biomatter utilizes its Intelligent Architecture™ platform to engineer proteins and enzymes with precise control for applications in health and sustainable manufacturing. The company provides environmentally friendly alternatives to traditional materials and enhances therapeutic efficacy through advanced protein design.

Protabit engineers novel proteins for industrial, agricultural, and healthcare applications. Their platform combines computational modeling with high-throughput screening and directed evolution to expand the diversity of protein sequences, enabling the creation of new proteins with desired functions.

Revolka offers the proprietary _ai_ Protein® platform that combines machine‑learning predictions with directed‑evolution lab data to design high‑functionality proteins—such as antibodies, enzymes, and peptides—in days instead of years. Clients can use the rapid “same‑day” AI antibody design service (RevoAb®) or engage in a full design‑to‑validation partnership, reducing experimental workload, accelerating discovery, and lowering R&D costs across pharma, biotech, and industrial sectors.

Hephaistos designs custom enzymes using protein engineering and machine learning to enable biocatalytic manufacturing of fine chemicals. Their purpose‑driven enzyme designs target reactions that are not achievable with existing biocatalysts, reducing production costs. The company offers end‑to‑end development from computational design to laboratory‑validated prototypes for industrial clients.

Puxano is a platform-based CRO integrating AI-driven protein design with structure-based protein research, including cryoEM. The company utilizes proprietary Design-to-Structure and Gene-to-Structure workflows to accelerate the development of novel vaccines, protein therapeutics, and biopesticides. Services span computational analysis, biochemical assays, and high-resolution structure determination.

Cyrus Biotechnology utilizes AI-driven protein design and deep mutagenesis to develop biologics targeting severe autoimmune diseases and COVID-19. Their platform has advanced over 30 discovery programs, focusing on IgG-driven conditions and engineered therapeutics that enhance efficacy and safety for patients.

Globin Solutions, Inc. develops heme-based antidotal therapies to treat human poisonings by utilizing globin chemistry and protein engineering techniques. Their focus is on creating effective treatments that can rapidly neutralize toxins, addressing a critical need in emergency medical care.

OpenProtein.AI offers a machine learning platform that enables biologists to enhance protein engineering processes, resulting in faster, more cost-effective, and reliable product development. By providing accessible ML tools, the platform addresses the limitations of traditional methods in protein design and optimization.

The startup develops a protein engineering platform that utilizes molecular biology and computational methods to create high-performance enzymes. These enzymes address challenges in diagnostics, life sciences, manufacturing, pharmaceuticals, and food ingredients, enabling clients to enhance their biological research capabilities.